S L Huskinson1, J E Naylor2, E A Townsend2, J K Rowlett3,2,4, B E Blough5, K B Freeman3,2. 1. Department of Psychiatry and Human Behavior, University of Mississippi Medical Center, 2500 N. State Street, Jackson, MS, 39216, USA. shuskinson@umc.edu. 2. Program in Neuroscience, University of Mississippi Medical Center, Jackson, MS, 39216, USA. 3. Department of Psychiatry and Human Behavior, University of Mississippi Medical Center, 2500 N. State Street, Jackson, MS, 39216, USA. 4. Tulane National Primate Research Center, Tulane University School of Medicine, Covington, LA, 70433, USA. 5. Center for Drug Discovery, Research Triangle Institute, Research Triangle Park, NC, 27709, USA.
Abstract
RATIONALE: Synthetic cathinones have become increasingly available as drugs of abuse. Distribution of these drugs is made possible by altering the chemical structures of prohibited cathinones and marketing them under misleading labels. Very little is known about the relative reinforcing effectiveness of new synthetic cathinones relative to known drugs of abuse. OBJECTIVE: We examined self-administration of three second-generation synthetic cathinones: alpha-pyrrolidinopentiophenone (alpha-PVP), 4-methyl-N-ethylcathinone (4-MEC), and 4-methyl-alpha-pyrrolidinopropiophenone (4-MePPP) relative to methamphetamine. METHOD: Male, Sprague-Dawley rats, implanted with intravenous catheters, were trained to self-administer methamphetamine (0.05 mg/kg/injection) under a fixed-ratio schedule. Following training, various doses of methamphetamine (0.006-0.1 mg/kg/injection), alpha-PVP (0.0015-0.1 mg/kg/injection), 4-MEC (0.1-3.2 mg/kg/injection), or 4-MePPP (0.1-0.8 mg/kg/injection) were available for self-administration in separate groups, followed by a behavioral-economics evaluation of the reinforcing effectiveness of each drug. RESULTS: For all drugs, at least one dose functioned as a reinforcer. Alpha-PVP and 4-MePPP maintained the highest numbers of infusions per session and both were more effective reinforcers relative to methamphetamine. 4-MEC and methamphetamine were not significantly different in terms of infusions per session or reinforcing effectiveness. CONCLUSION: Emerging synthetic cathinones whose primary pharmacological mechanism is to block dopamine uptake but with little effects on monoamine release or serotonin uptake may have a greater degree of abuse potential compared with known abused stimulants.
RATIONALE: Synthetic cathinones have become increasingly available as drugs of abuse. Distribution of these drugs is made possible by altering the chemical structures of prohibited cathinones and marketing them under misleading labels. Very little is known about the relative reinforcing effectiveness of new synthetic cathinones relative to known drugs of abuse. OBJECTIVE: We examined self-administration of three second-generation synthetic cathinones: alpha-pyrrolidinopentiophenone (alpha-PVP), 4-methyl-N-ethylcathinone (4-MEC), and 4-methyl-alpha-pyrrolidinopropiophenone (4-MePPP) relative to methamphetamine. METHOD: Male, Sprague-Dawley rats, implanted with intravenous catheters, were trained to self-administer methamphetamine (0.05 mg/kg/injection) under a fixed-ratio schedule. Following training, various doses of methamphetamine (0.006-0.1 mg/kg/injection), alpha-PVP (0.0015-0.1 mg/kg/injection), 4-MEC (0.1-3.2 mg/kg/injection), or 4-MePPP (0.1-0.8 mg/kg/injection) were available for self-administration in separate groups, followed by a behavioral-economics evaluation of the reinforcing effectiveness of each drug. RESULTS: For all drugs, at least one dose functioned as a reinforcer. Alpha-PVP and 4-MePPP maintained the highest numbers of infusions per session and both were more effective reinforcers relative to methamphetamine. 4-MEC and methamphetamine were not significantly different in terms of infusions per session or reinforcing effectiveness. CONCLUSION: Emerging synthetic cathinones whose primary pharmacological mechanism is to block dopamine uptake but with little effects on monoamine release or serotonin uptake may have a greater degree of abuse potential compared with known abused stimulants.
Authors: Jennifer E Naylor; Kevin B Freeman; Bruce E Blough; William L Woolverton; Sally L Huskinson Journal: Drug Alcohol Depend Date: 2015-02-11 Impact factor: 4.492
Authors: Shawn M Aarde; Kevin M Creehan; Sophia A Vandewater; Tobin J Dickerson; Michael A Taffe Journal: Psychopharmacology (Berl) Date: 2015-05-01 Impact factor: 4.530
Authors: Lucas R Watterson; Peter R Kufahl; Natali E Nemirovsky; Kaveish Sewalia; Megan Grabenauer; Brian F Thomas; Julie A Marusich; Scott Wegner; M Foster Olive Journal: Addict Biol Date: 2012-07-11 Impact factor: 4.280
Authors: Craig P Motbey; Kelly J Clemens; Nadine Apetz; Adam R Winstock; John Ramsey; Kong M Li; Naomi Wyatt; Paul D Callaghan; Michael T Bowen; Jennifer L Cornish; Iain S McGregor Journal: J Psychopharmacol Date: 2013-06-05 Impact factor: 4.153
Authors: Gregory L Powell; Gabriella Cabrera-Brown; Mark D Namba; Janet L Neisewander; Julie A Marusich; Joshua S Beckmann; Cassandra D Gipson Journal: Drug Alcohol Depend Date: 2019-06-20 Impact factor: 4.492
Authors: Katharine H Nelson; Hayley N Manke; Aikerim Imanalieva; Kenner C Rice; Anthony L Riley Journal: Pharmacol Biochem Behav Date: 2019-08-21 Impact factor: 3.533
Authors: Brenda M Gannon; Melson P Mesmin; Agnieszka Sulima; Kenner C Rice; Gregory T Collins Journal: Psychopharmacology (Berl) Date: 2018-09-29 Impact factor: 4.530
Authors: E Andrew Townsend; Paul T Bremer; Kaycee E Faunce; S Stevens Negus; Alaina M Jaster; Hannah L Robinson; Kim D Janda; Matthew L Banks Journal: ACS Chem Neurosci Date: 2020-04-22 Impact factor: 4.418
Authors: Brenda M Gannon; Kayla I Galindo; Melson P Mesmin; Agnieszka Sulima; Kenner C Rice; Gregory T Collins Journal: Neuropharmacology Date: 2017-08-12 Impact factor: 5.250
Authors: E Andrew Townsend; S Stevens Negus; S Barak Caine; Morgane Thomsen; Matthew L Banks Journal: Neuropsychopharmacology Date: 2019-02-28 Impact factor: 7.853
Authors: E Andrew Townsend; Jennifer E Naylor; S Stevens Negus; Shelley R Edwards; Hina N Qureshi; Hunter W McLendon; Christopher R McCurdy; Coco N Kapanda; Jussara M do Carmo; Fernanda S da Silva; John E Hall; Kenneth J Sufka; Kevin B Freeman Journal: Psychopharmacology (Berl) Date: 2017-05-31 Impact factor: 4.530